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Background
Tamoxifen has been a standard adjuvant hormonal treat-
ment for estrogen receptor ER positive breast cancer, both
in pre and postmenopausal women. It has been noticed
that some breast cancer patients don’t respond to tamoxi-
fen as others. In the presented study, HER2 receptor status
has been studied as a probable prognostic index regarding
the local recurrence & disease related mortality & to dif-
ferentiate responders from non-responders to tamoxifen
treatment.
Methods
205 patients in the oncology center of Merjan Hospital,
Hilla, Iraq who had mastectomy performed and histo-
pathology done studying the ER and HER2 receptor status,
all of which ER positive and of early stages (I and II) breast
cancer, had been studied prospectively between the fifth of
June 2010 and the 19th of June 2011 regarding the local
recurrence and mortality during this period. All the
patients had been given Tamoxifen tablet 20mg/day.
Results
56 (27.3%) were HER2 receptors +ve, and 149 (72.7%)
were HER2 receptor -ve . 19 (33.9%) and 9(16%) of the
HER2 +ve patients had local recurrence and died due
to the disease respectively during the follow up period.
30 (20.1%) and 14 (9.4%) of the HER -ve patients had
local recurrence and died of the disease respectively dur-
ing the follow up period.
Conclusion
I found a significant difference in the disease local
recurrence and mortality of ER+ve HER2 receptor +ve
as compared with the ER+ve HER2 receptor -ve in favor
of the latter and the ER+veHER2 receptor -ve had a
much better prognosis.
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